Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Insulet (NASDAQ:PODD - Get Rating) had its price objective lifted by research analysts at Canaccord Genuity Group from $290.00 to $310.00 in a note issued to investors on Friday, The Fly reports. The brokerage presently has a "buy" rating on the medical instruments supplier's stock. Canaccord Genuity Group's price target would indicate a potential upside of 3.81% from the stock's previous close.

PODD has been the subject of a number of other reports. Barclays started coverage on Insulet in a research report on Monday, October 17th. They issued an "equal weight" rating and a $238.00 price objective for the company. Morgan Stanley raised their price objective on Insulet from $273.00 to $300.00 and gave the company an "equal weight" rating in a research report on Friday. Piper Sandler raised Insulet from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $235.00 to $340.00 in a report on Friday. Canaccord Genuity Group lifted their price target on Insulet from $250.00 to $290.00 and gave the stock a "buy" rating in a report on Friday, August 5th. Finally, StockNews.com cut Insulet from a "hold" rating to a "sell" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $305.87.Insulet Stock Up 16.9 %

NASDAQ:PODD opened at $298.62 on Friday. The company has a debt-to-equity ratio of 3.28, a quick ratio of 3.54 and a current ratio of 4.69. The company has a market cap of $20.72 billion, a PE ratio of 510.70 and a beta of 0.79. Insulet has a 52-week low of $181.00 and a 52-week high of $324.81. The stock has a 50-day simple moving average of $245.49 and a 200 day simple moving average of $236.76.

Insulet (NASDAQ:PODD - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.21 by ($0.27). The company had revenue of $299.40 million during the quarter, compared to the consensus estimate of $290.87 million. Insulet had a net margin of 2.94% and a return on equity of 13.83%. The firm's revenue for the quarter was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. On average, sell-side analysts expect that Insulet will post 0.76 EPS for the current fiscal year. Insider Buying and Selling

In other Insulet news, EVP Bret Christensen sold 2,900 shares of Insulet stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total transaction of $766,296.00. Following the transaction, the executive vice president now directly owns 19,551 shares of the company's stock, valued at approximately $5,166,156.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Insulet news, EVP Bret Christensen sold 2,900 shares of Insulet stock in a transaction dated Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total transaction of $766,296.00. Following the transaction, the executive vice president now directly owns 19,551 shares of the company's stock, valued at approximately $5,166,156.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Shacey Petrovic sold 15,000 shares of Insulet stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $231.80, for a total value of $3,477,000.00. Following the transaction, the director now directly owns 13,695 shares in the company, valued at $3,174,501. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders. Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SeaCrest Wealth Management LLC acquired a new position in Insulet during the 2nd quarter worth approximately $26,000. Institutional & Family Asset Management LLC raised its stake in Insulet by 261.3% during the 1st quarter. Institutional & Family Asset Management LLC now owns 112 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 81 shares during the period. Quent Capital LLC raised its stake in Insulet by 310.7% during the 1st quarter. Quent Capital LLC now owns 115 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 87 shares during the period. Wolff Wiese Magana LLC raised its stake in Insulet by 153.6% during the 1st quarter. Wolff Wiese Magana LLC now owns 142 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 86 shares during the period. Finally, Elequin Capital LP acquired a new position in Insulet during the 1st quarter worth approximately $40,000. Insulet Company Profile (Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.See AlsoGet a free copy of the StockNews.com research report on Insulet (PODD)Datadog Doesn’t Belong In The Doghouse Mixed Results Actually Bring More Optimism than Risk for AMDNikola Shares Fall Even As EV Maker Beats Q3 Expectations Energy Transfer Raises Guidance, But Stock Lower On Revenue MissPapa John’s Falls Flat On Earnings, Shares Set To Rise

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Insulet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.

While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.